McKenna's Pharmacology for Nursing, 2e

987

Index

MAO inhibitors (monoamine oxidase inhibitors). See Monoamine oxidase (MAO) inhibitors Maraviroc, 127, 137, 141 Marigold leaves and flowers, 966 Marijuana, 3 Mast cell, 228, 230 stabiliser, 864, 865, 877, 880–881 adverse effects, 880 care considerations, 880–881 contraindications and cautions, 880 pharmacokinetics, 880 therapeutic actions and indications, 880 MDMA, 67 Measles, mumps, rubella (MMR) vaccine, 273, 281, 284 autism and, 278 Measuring systems, 55 Mebendazole, 179, 183, 185–186 Mebeverine, 927 nurse and midwife’s role, 49 person’s role, 49 reporting, 49–50 Medicines Adverse Reaction Committee (MARC), 65 Medicines and Medical Devices Safety Authority, 65 Mefenamic acid, 247 Mefloquine, 166, 167 Megaloblastic anaemias, 774, 776 agents used to treat, 787–789 adverse effects, 788 care considerations, 788–789 contraindications and cautions, 788 pharmacokinetics, 788 therapeutic actions and indications, 787–788 Megestrol, 212, 214 Melatonin, 966 Meloxicam, 241, 247 Melphalan, 195, 197 Memantine, 492, 494 Menarche, 596, 599 Meningococcal vaccine, 279 Menopausal gonadotrophin, 617, 618 Menopause, 596, 601 combination drugs, 609 hormone replacement therapy (HRT), 612–613 Menstrual cycle, 596, 599–600 Medical Letter , 12 Medication errors preventing, 46–50 Medicines Monitoring (M2), 65 Medroxyprogesterone, 607, 608

hyperlipidaemias, 733 treating, 734–735 lipoproteins, 72, 73–74, 732 high-density (HDLs), 729, 732 levels, variation in, 731 low-density (LDLs), 729, 732 Metaraminol, 456, 458, 676 Metastasis, 190, 191 Metformin, 573, 586, 588–589, 590 Methotrexate, 190, 200, 202, 203 Methoxy polyethylene glycol-epoetin beta, 777, 778 Methoxyflurane, 420, 422 Methyldopa, 676 Methylnaltrexone, 921 Methylphenidate, 67, 334, 333, 347, 348 school nursing, 349 Methylprednisolone, 539, 542, 543 Metoclopramide, 200, 929, 931, 934 Metoprolol, 471, 482, 676, 714, 716, 722–723 Metronidazole, 163, 172–174, 953 Mianserin, 331 Miconazole, 157, 952 Methadone, 401, 402 Methamphetamine, 67 Microfibrillar collagen, 769, 770 Midazolam, 354, 416, 420, 421 Midbrain, 292, 298–299 Midodrine, 677 Midwifery, 42, 43, 49 Mifepristone, 620 Migraine headache, 397, 409–410 drugs for. See Antimigraine agents gender considerations, 410 Milk thistle, 966 Milk vetch, 966 Milrinone, 686, 692 MIMS , 11 Mineralocorticoids, 536, 542–543, 547–548 adverse effects, 547 care considerations, 548 contraindications and cautions, 547 drug–drug interactions, 547 duration of effect, 539 pharmacokinetics, 547 therapeutic actions and indications, 547 Minocycline, 114 Minoxidil, 666, 674 Miosis, 487, 490 Mirtazapine, 331 Misoprostol, 620, 896, 899, 901, 910–911 Mistletoe leaves, 966 Mitochondria, 72, 75 Mitomycin, 205, 206 Mitotic inhibitors, 191, 209–212 adverse effects, 210 care considerations, 211–212 contraindications and cautions, 210 drug–drug interactions, 210–211 pharmacokinetics, 210 therapeutic actions and indications, 210 Mitoxantrone, 205, 207

MMR vaccine, 281, 284 autism and, 278 Moclobemide, 331 Modafinil, 347 Mometasone furoate, 954 Momordica charantia , 966

Monoamine oxidase (MAO), 444, 449 Monoamine oxidase (MAO) inhibitors, 316, 323–325 adverse effects, 323–324 care considerations, 325 contraindications and cautions, 323

drug–drug interactions, 324 drug–food interactions, 324 pharmacokinetics, 323

therapeutic actions and indications, 323 Monobactum antibiotic, 104–106, 122 adverse effects, 105 care considerations, 105–106 contraindications and cautions, 105 pharmacokinetics, 105 therapeutic actions and indications, 104 Monoclonal antibodies, 258, 263, 264–265, 266–267 adverse effects, 267 care considerations, 267–268 contraindications and cautions, 267 drug–drug interactions, 267 pharmacokinetics, 267 therapeutic actions and indications, 266–267 Monocytes/macrophages, 228, 230–231 Montelukast, 865, 877–879 “Morning-after” pill, 608, 610, 611 Morphine, 67, 398, 401, 402, 403–404, 406 Motility, 891–892 Motor functions, 300 Moxifloxacin, 106, 107 Mucolytics, 842, 859–861 adverse effects, 860 care considerations, 860–861 contraindications and cautions, 860 pharmacokinetics, 860 therapeutic actions and indications, 859 Mucosal layer, 890 Mucous membranes, 229 Mumps virus vaccine, 281, 284 Mupirocin, 951 Muscarinic receptors, 444, 451 Muscle relaxants, 385–395 adults, 386 centrally acting skeletal muscle relaxants, 388–390 adverse effects, 389 care considerations, 390 contraindications and cautions, 389 drug–drug interactions, 389 pharmacokinetics, 389 therapeutic actions and indications, 388–389 cerebral palsy, 393–394 children, 386 direct-acting skeletal muscle relaxants, 390–393 adverse effects, 391–392

Menstruation, 596, 600 Mepivacaine, 425, 426 Mercaptopurine, 200, 201, 203

Meropenem, 87, 97, 98 Mesalazine, 242, 923

Mesna, 197, 198 Mesterolone, 629 Metabolic syndrome, 729, 730 Metabolism, 23, 551, 553, 731–735 cholesterol, 732–733